143 results on '"Sihag S"'
Search Results
2. Blood metabolites of murrah buffalo heifer on supplementation of different sources of rumen bypass proteins
- Author
-
Kumari, A., Gulati, H.K., Kumar, S., Sihag, S., and Kumar, M.
- Published
- 2021
- Full Text
- View/download PDF
3. EP07.04-04 High-Risk Clinicopathologic and Genomic Features of Recurrence in Stage I Lung Adenocarcinoma
- Author
-
Fick, C.N., primary, Dunne, E.G., additional, Mastrogiacomo, B., additional, Tan, K.S., additional, Toumbacaris, N., additional, Adusumilli, P.S., additional, Rocco, G., additional, Molena, D., additional, Huang, J., additional, Park, B.J., additional, Bott, M.J., additional, Rusch, V.R., additional, Sihag, S., additional, Isbell, J.M., additional, and Jones, D.R., additional
- Published
- 2023
- Full Text
- View/download PDF
4. Effect of dietary inclusion of spent grains on the performance of growing buffalo calves
- Author
-
Kumar, S., primary, Sihag, S., additional, and Sihag, Z. S., additional
- Published
- 2023
- Full Text
- View/download PDF
5. FOLFOX-Based Chemoradiation as Non-Operative Management for Esophageal Adenocarcinoma
- Author
-
Rouf, R., primary, Ku, G., additional, Cowzer, D., additional, Harrington, C., additional, Maron, S., additional, Janjigian, Y., additional, Ilson, D.H., additional, Molena, D., additional, Sihag, S., additional, Hajj, C., additional, Crane, C.H., additional, and Wu, A.J., additional
- Published
- 2022
- Full Text
- View/download PDF
6. Induction of Cardiac Allograft Tolerance Across a Full MHC Barrier in Miniature Swine by Donor Kidney Cotransplantation
- Author
-
Madariaga, M.L., Michel, S.G., Tasaki, M., Villani, V., La Muraglia, G.M., II, Sihag, S., Gottschall, J., Farkash, E.A., Shimizu, A., Allan, J.S., Sachs, D.H., Yamada, K., and Madsen, J.C.
- Published
- 2013
- Full Text
- View/download PDF
7. SO-6 Novel frailty index predicts short-term outcomes after esophagectomy in elderly patients with esophageal cancer
- Author
-
Boerner, T., primary, Tin, A., additional, Vickers, A., additional, Harrington, C., additional, Janjigian, Y., additional, Ilson, D., additional, Wu, A., additional, Bott, M., additional, Isbell, J., additional, Park, B., additional, Sihag, S., additional, Jones, D., additional, Downey, R., additional, Shahrokni, A., additional, and Molena, D., additional
- Published
- 2022
- Full Text
- View/download PDF
8. Recipient-Matching of Passenger Leukocytes Prolongs Survival of Donor Lung Allografts in Miniature Swine.: Abstract# D2809
- Author
-
Madariaga, M., Michel, S., La Muraglia, G., II, Sihag, S., Leonard, D., Powell, H., Farkash, E., Colvin, R., Cetrulo, C., Jr, Huang, C., Sachs, D., Madsen, J., and Allan, J.
- Published
- 2014
9. Changing Pattern of Prices and Arrivals of Agricultural Commodities Through e-NAM: A Case Study of Sirsa Apmc in Haryana
- Author
-
Singh Abhey, Kiran, and Sihag Shakuntla
- Subjects
e-nam ,agricultural commodities ,infrastructure facilities ,arrivals and price pattern ,towary rolne ,infrastruktura ,wzorce przywozów i cen ,l10 ,m31 ,Regional economics. Space in economics ,HT388 ,Economics as a science ,HB71-74 - Abstract
The study examined the market profile and status of Electronic National Agriculture Market (e-NAM) in Sirsa Agricultural Produce Market Committee (APMC) The study also analysed the arrival and price pattern of major agricultural commodities before and after the implementation of e-NAM in the study area.
- Published
- 2023
- Full Text
- View/download PDF
10. Survival and Patterns of Failure in Oligometastatic Esophagogastric Cancer
- Author
-
Hilal, L., primary, Ku, G., additional, Molena, D., additional, Janjigian, Y., additional, Ilson, D.H., additional, Maron, S., additional, Sihag, S., additional, Yoon, S.S., additional, Strong, V., additional, Crane, C.H., additional, Gomez, D.R., additional, and Wu, A.J., additional
- Published
- 2020
- Full Text
- View/download PDF
11. Prolonged Survival of Pulmonary Allografts between Highly Inbred Miniature Swine without Immunosuppression.: Abstract# 1458 Poster Board #-Session: P20-IV
- Author
-
Sihag, S., Aoyama, A., Gottschall, J. D., Wain, J. C., Arn, J. S., Farkash, E. A., Smith, R. N., Madsen, J. C., Rosengard, B. R., Sachs, D. H., and Allan, J. S.
- Published
- 2012
12. COLON CAPSULE ENDOSCOPY (CCE) IS AN EFFECTIVE FILTER TEST FOR COLONIC POLYP SURVEILLANCE
- Author
-
Semenov, S, additional, Manoharan, T, additional, Sihag, S, additional, Hazel, K, additional, Ismail, MS, additional, Molloy, D, additional, Ryan, B, additional, Breslin, N, additional, O’Connor, A, additional, and McNamara, D, additional
- Published
- 2020
- Full Text
- View/download PDF
13. SIMETHICONE CLEARS THE WAY FOR CAPSULES
- Author
-
Douglas, A, additional, Sihag, S, additional, Semenov, S, additional, Ryan, B, additional, O’Connor, A, additional, Breslin, N, additional, and McNamara, D, additional
- Published
- 2020
- Full Text
- View/download PDF
14. SMALL BOWEL POLYPECTOMY FOR THE MANAGEMENT OF PEUTZ-JEGHER ASSOCIATED RECURRENT INTUSSUSCEPTION
- Author
-
Ismail, MS, additional, Semenov, S, additional, Sihag, S, additional, and McNamara, D, additional
- Published
- 2020
- Full Text
- View/download PDF
15. THE ADDITION OF CASTOR OIL AS A BOOSTER IN COLON CAPSULE REGIMENS SIGNIFICANTLY IMPROVES COMPLETION RATES AND POLYP DETECTION
- Author
-
Semenov, S, additional, Atiyekeogbebe, R, additional, Ismail, MS, additional, Sihag, S, additional, McCarthy, E, additional, Ryan, B, additional, Breslin, N, additional, O’Connor, A, additional, and McNamara, D, additional
- Published
- 2020
- Full Text
- View/download PDF
16. IMPROVING QUALITY IN COLON CAPSULE ENDOSCOPY; EFFECTS OF DIFFERENT BOWEL PREPARATION REGIMENS
- Author
-
Syafiq Ismail, M, additional, Semenov, S, additional, Sihag, S, additional, Breslin, N, additional, O’Connor, A, additional, Ryan, B, additional, and McNamara, D, additional
- Published
- 2020
- Full Text
- View/download PDF
17. CLINICAL OUTCOME OF PATIENTS EXAMINED BY SMALL BOWEL CAPSULE ENDOSCOPY WITH NON-SPECIFIC ENTERITIS
- Author
-
Sihag, S, additional, Tan, B, additional, Ismail, MS, additional, Semenov, S, additional, Ryan, B, additional, O’Connor, A, additional, Breslin, N, additional, and McNamara, D, additional
- Published
- 2020
- Full Text
- View/download PDF
18. IS IT WORTH REPEATING CAPSULE ENDOSCOPY (CE) IN SUSPECTED SMALL BOWEL BLEEDING?
- Author
-
Sihag, S, additional, McCarthy, E, additional, Semenov, S, additional, Syafiq Ismail, M, additional, Molloy, D, additional, Ryan, B, additional, O’Connor, A, additional, Breslin, N, additional, and McNamara, D, additional
- Published
- 2020
- Full Text
- View/download PDF
19. P203 FIT and FC as a surrogate non-invasive marker for mucosal healing in inflammatory bowel disease
- Author
-
ISMAIL, M S, primary, Murphy, G, additional, Kelly, C, additional, O’Riordan, F, additional, Semenov, S, additional, Sihag, S, additional, Breslin, N, additional, Anthony, O, additional, Ryan, B, additional, and McNamara, D, additional
- Published
- 2020
- Full Text
- View/download PDF
20. Genetic Determinants of Chemoradiation Response and Survival in Locally Advanced Esophageal Carcinoma Treated with Trimodality Therapy
- Author
-
Pitter, K.L., primary, Casey, D.L., additional, Oh, P., additional, Setton, J., additional, Ku, G., additional, Ilson, D.H., additional, Janjigian, Y., additional, Bains, M.S., additional, Jones, D., additional, Molena, D., additional, Crane, C.H., additional, Sihag, S., additional, and Wu, A.J., additional
- Published
- 2019
- Full Text
- View/download PDF
21. Mustard cake as a source of dietary protein for growing lambs
- Author
-
Anil Kumar, G.K., Panwar, V.S., Yadav, K.R., and Sihag, S.
- Published
- 2002
- Full Text
- View/download PDF
22. Nutrigenomic evaluation of garlic (Allium sativum) and holy basil (Ocimum sanctum) leaf powder supplementation on growth performance and immune characteristics in broilers
- Author
-
Sheoran, N., primary, Kumar, R., additional, Kumar, A., additional, Batra, K., additional, Sihag, S., additional, Maan, S., additional, and Maan, N. S., additional
- Published
- 2017
- Full Text
- View/download PDF
23. Destroying the culture of secrecy: empowerment and dignity through right to information: a case study of MKSS in Rajasthan
- Author
-
Sihag, S., primary and Sihag, S., additional
- Published
- 2009
- Full Text
- View/download PDF
24. Recipient-Matching of Passenger Leukocytes Prolongs Survival of Donor Lung Allografts in Miniature Swine.
- Author
-
Madariaga, M., primary, Michel, S., additional, La Muraglia, G., additional, Sihag, S., additional, Leonard, D., additional, Powell, H., additional, Farkash, E., additional, Colvin, R., additional, Cetrulo, C., additional, Huang, C., additional, Sachs, D., additional, Madsen, J., additional, and Allan, J., additional
- Published
- 2014
- Full Text
- View/download PDF
25. Integrated analysis of protein composition, tissue diversity, and gene regulation in mouse mitochondria
- Author
-
Mootha, V.K., Bunkenborg, J., Olsen, J.V., Hjerrild, M., Wisniewski, J.R., Stahl, E., Bolouri, M.S., Ray, H.N., Sihag, S., Kamal, M., Patterson, N., Lander, E.S., and Mann, M.
- Published
- 2003
26. Mitigating Lung Ischemia-Reperfusion Injury in Miniature Swine
- Author
-
Madariaga, M.L.L., primary, Sihag, S., additional, Gottschall, J.D., additional, Farkash, E.A., additional, Haas, M.S., additional, Carroll, M.C., additional, and Allan, J.S., additional
- Published
- 2013
- Full Text
- View/download PDF
27. Comparison of perioperative outcomes following open versus minimally invasive Ivor Lewis oesophagectomy at a single, high-volume centre
- Author
-
Sihag, S., primary, Wright, C. D., additional, Wain, J. C., additional, Gaissert, H. A., additional, Lanuti, M., additional, Allan, J. S., additional, Mathisen, D. J., additional, and Morse, C. R., additional
- Published
- 2012
- Full Text
- View/download PDF
28. EFFECT OF DIETARY SUPPLEMENTATION OF YEAST ON FORE, INTERMEDIATE AND HIND PORTIONS OF RABBITS RAISED UNDER CAGE AND PEN SYSTEM OF HOUSING.
- Author
-
Khanna, S., Gulati, H. K., and Sihag, S. S.
- Subjects
DIETARY supplements ,YEAST ,RABBITS ,EUROPEAN rabbit ,LEPORIDAE - Abstract
At 13 weeks of age, rabbits raised under cage system of housing with 2% yeast supplementation in their concentrate (T
2 ) had significantly higher total weight gain than the pen system and without yeast supplementation (T3 ). The rabbits reared under pen system with (T4 ) or without yeast supplementation (T3 ) had significantly higher portion of fore part hind part and lower portion of intermediate part than the rabbits reared under cage system with (T2 ) or without yeast supplementation (T1 ). [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
29. A Real-World Assessment of Stage I Lung Cancer Through Electronic Nose Technology.
- Author
-
Rocco G, Pennazza G, Tan KS, Vanstraelen S, Santonico M, Corba RJ, Park BJ, Sihag S, Bott MJ, Crucitti P, Isbell JM, Ginsberg MS, Weiss H, Incalzi RA, Finamore P, Longo F, Zompanti A, Grasso S, Solomon SB, Vincent A, McKnight A, Cirelli M, Voli C, Kelly S, Merone M, Molena D, Gray K, Huang J, Rusch VW, Bains MS, Downey RJ, Adusumilli PS, and Jones DR
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Prospective Studies, Lung Neoplasms pathology, Electronic Nose, Neoplasm Staging
- Abstract
Introduction: Electronic nose (E-nose) technology has reported excellent sensitivity and specificity in the setting of lung cancer screening. However, the performance of E-nose specifically for early-stage tumors remains unclear. Therefore, the aim of our study was to assess the diagnostic performance of E-nose technology in clinical stage I lung cancer., Methods: This phase IIc trial (NCT04734145) included patients diagnosed with a single greater than or equal to 50% solid stage I nodule. Exhalates were prospectively collected from January 2020 to August 2023. Blinded bioengineers analyzed the exhalates, using E-nose technology to determine the probability of malignancy. Patients were stratified into three risk groups (low-risk, [<0.2]; moderate-risk, [≥0.2-0.7]; high-risk, [≥0.7]). The primary outcome was the diagnostic performance of E-nose versus histopathology (accuracy and F1 score). The secondary outcome was the clinical performance of the E-nose versus clinicoradiological prediction models., Results: Based on the predefined cutoff (<0.20), E-nose agreed with histopathologic results in 86% of cases, achieving an F1 score of 92.5%, based on 86 true positives, two false negatives, and 12 false positives (n = 100). E-nose would refer fewer patients with malignant nodules to observation (low-risk: 2 versus 9 and 11, respectively; p = 0.028 and p = 0.011) than would the Swensen and Brock models and more patients with malignant nodules to treatment without biopsy (high-risk: 27 versus 19 and 6, respectively; p = 0.057 and p < 0.001)., Conclusions: In the setting of clinical stage I lung cancer, E-nose agrees well with histopathology. Accordingly, E-nose technology can be used in addition to imaging or as part of a "multiomics" platform., Competing Interests: Disclosure Dr. Rocco has a financial relationship with Scanlan, Merck, and Medtronic. Dr. Prasad S. Adusumilli serves as consultant for ATARA Biotherapeutics, Bayer, Carisma Therapeutics, Imugene, ImmPactBio, and Johnson & Johnson. Dr. Park has received honoraria from Intuitive Surgical, AstraZeneca, and Medtronic, serves as a consultant to Ceevra, and has received institutional research support from Intuitive Surgical. Dr. Bott is a consultant for AstraZeneca Pharmaceuticals, Iovance Biotherapeutics, and Intuitive Surgical and receives research support from Obsidian Therapeutics. Dr. Molena serves on a steering committee for AstraZeneca and as a consultant for Johnson & Johnson, Bristol-Myers Squibb, AstraZeneca, and Boston Scientific, and has been an invited speaker for Merck and Genentech. Dr. Isbell has served as an advisory board member for AstraZeneca and Merck and as an uncompensated steering board member for Genentech, has received institutional research support from ArcherDx/Invitae, Guardant Health, GRAIL, and Intuitive Surgical and travel support from Intuitive Surgical, and has equity or ownership interest in LumaCyte. Dr. Rusch receives grant support (institutional) from Genelux and Genentech, travel support from Intuitive Surgical, and travel support and payments from the National Institutes of Health/Coordinating Center for Clinical Trials. Dr. Solomon serves as a consultant for GE Healthcare and Merck and on the data monitoring committee for Candel Therapeutics and Impact Biotech. Dr. Jones is a member of the Advisory Council for AstraZeneca and Advisory Committee for More Health, has been a speaker for DAVA Oncology, and receives research grant support from Merck. The remaining authors declare no conflict of interest., (Copyright © 2024 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
30. Outcomes of Patients Undergoing Segmentectomy for Occult Node-Positive Clinical Stage IA Lung Cancer.
- Author
-
Nobel TB, Tan KS, Adusumilli PS, Bains MS, Downey RJ, Gray K, Huang J, Isbell JM, Molena D, Park BJ, Rocco G, Rusch VW, Sihag S, Jones DR, and Bott MJ
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Treatment Outcome, Neoplasm Recurrence, Local epidemiology, Retrospective Studies, Survival Rate trends, Lymph Nodes pathology, Lymph Nodes surgery, Lung Neoplasms surgery, Lung Neoplasms pathology, Lung Neoplasms mortality, Pneumonectomy methods, Carcinoma, Non-Small-Cell Lung surgery, Carcinoma, Non-Small-Cell Lung mortality, Carcinoma, Non-Small-Cell Lung pathology, Neoplasm Staging, Lymphatic Metastasis
- Abstract
Background: Results of recent clinical trials suggest that segmentectomy may be an acceptable alternative to lobectomy for selected patients with early-stage non-small cell lung cancer (NSCLC). Increased use of segmentectomy may result in a concomitant increase in occult node-positive (N+) disease on surgical pathology examination. The optimal management for such patients remains unknown., Methods: Clinicopathologic data were abstracted from a prospective institutional database to identify patients with pathologic N+ disease after segmentectomy for cT1 N0 M0 NSCLC. Propensity score matching identified a comparable lobectomy cohort for assessment of cumulative incidence of recurrence and overall survival (OS)., Results: Of 759 included patients, 27 (4%) had nodal upstaging on the final pathology report. Of these 27 patients, 4 (15%) had skip metastasis to N2 stations, and 20 (74%) received adjuvant therapy; no completion lobectomies were performed. Ten patients (37%) had disease recurrence: 3 isolated locoregional (11%) and 7 distant (26%). The median time to recurrence among patients with recurrence was 1.8 years; OS after recurrence was 3.4 years. After 5:1 matching with 109 patients who underwent lobectomy, all variables were balanced between the groups, except pathologic N2 stage and open surgical approach. The 5-year cumulative incidence of recurrence was not significantly different between segmentectomy and lobectomy (42% vs 52%, respectively; Gray's P = .1). The 5-year OS (63% and 50%) and rate of locoregional recurrence (12% vs 13%) were not statistically different between the groups., Conclusions: Patients with occult N+ disease after segmentectomy for cT1 N0 M0 NSCLC had limited isolated locoregional recurrences and outcomes similar to those in patients who underwent lobectomy. Lobectomy may not provide an advantage in these patients., Competing Interests: Disclosures James M. Isbell has served as an advisory board member for AstraZeneca and Merck; has served as an uncompensated steering board member for Genentech; has received travel support from Intuitive Surgical; and has equity or ownership interest in LumaCyte. Daniela Molena has served on a steering committee for AstraZeneca; has served as a consultant for Johnson & Johnson, Bristol Myers Squibb, AstraZeneca, and Boston Scientific; and has been an invited speaker for Merck and Genentech. Bernard J. Park has received honoraria from Intuitive Surgical, AstraZeneca, and Medtronic; and has served as a consultant for Ceevra. Gaetano Rocco has a financial relationship with Scanlan, Merck, and Medtronic. Valerie W. Rusch has received other support from DaVinci Surgery; has received nonfinancial support from Bristol Myers Squibb; and has received personal fees from the NIH Coordinating Center for Clinical Trials. Smita Sihag has served as a member of the AstraZeneca advisory board. David R. Jones has served as a member of the advisory council for AstraZeneca and the Advisory Committee for More Health; and has been a speaker for DAVA Oncology. Matthew J. Bott has served as a consultant for AstraZeneca Pharmaceuticals, Iovance Biotherapeutics, and Intuitive Surgical., (Copyright © 2024 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
31. Determinants of successful minimally invasive surgery (MIS) for resectable non-small cell lung cancer (NSCLC) after neoadjuvant therapy.
- Author
-
Chu NQ, Tan KS, Dycoco J, Adusumilli PS, Bains MS, Bott MJ, Downey RJ, Gray KD, Huang J, Isbell JM, Molena D, Sihag S, Rocco G, Jones DR, Park BJ, and Rusch VW
- Abstract
Objective: MIS (VATS, RATS) for pulmonary resection is standard in early stage NSCLC as it is associated with better perioperative outcomes than thoracotomy. MIS for resection of more advanced NSCLC (Stages IB-IIIB) treated with neoadjuvant therapy has been utilized. However, the determinants of success are not well-defined., Methods: A single institution retrospective review of a prospectively maintained database was conducted, querying for patients with clinical Stage IB-IIIB NSCLC who had resection after neoadjuvant systemic therapy without radiation from 2013-2022. Patients were grouped by surgical approach, open vs. MIS. Successful MIS was defined by no conversion, R0 resection, and no major (≥grade 3) morbidity. Analyses by intent-to-treat assessed outcomes by Wilcoxon rank sum test and Fisher's exact test. (MVA identified variables that contributed to successful MIS resection., Results: Of 627 eligible patients, 360 (57%) had open and 267 (43%) had MIS procedures. Most patients (79.1%) received neoadjuvant platinum-based chemotherapy, and 21.9% were treated with immunotherapy or targeted therapy alone or combined with chemotherapy. Among MIS resections, 179 (67%) were performed by VATS and 88 (33%) by RATS. The conversion rate was 16% (n=43). Successful MIS resection was achieved in 77% of patients. MVA showed that pre-treatment clinical N stage was a significant determinant of success, but not pre-treatment clinical T stage or type of neoadjuvant therapy., Conclusion: Following neoadjuvant systemic therapy for clinical stage IB-IIIB NSCLC, MIS resection can be successfully accomplished and should be considered in appropriate patients. Presence of pre-treatment nodal disease is associated with higher odds of conversion, major morbidity, and incomplete resection., (Copyright © 2024. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
32. A Novel Frailty Index Can Predict the Short-Term Outcomes of Esophagectomy in Older Patients with Esophageal Cancer.
- Author
-
Boerner T, Sewell M, Tin AL, Vickers AJ, Harrington-Baksh C, Bains MS, Bott MJ, Park BJ, Sihag S, Jones DR, Downey RJ, Shahrokni A, and Molena D
- Subjects
- Humans, Aged, Male, Female, Treatment Outcome, Postoperative Complications epidemiology, Aged, 80 and over, Esophagectomy methods, Esophageal Neoplasms surgery, Esophageal Neoplasms mortality, Frailty complications
- Abstract
Background: Frailty, rather than age, is associated with postoperative morbidity and mortality. We sought to determine whether preoperative frailty as defined by a novel scoring system could predict the outcomes among older patients undergoing esophagectomy. Methods: We identified patients 65 years or older who underwent esophagectomy between 2011 and 2021 at our institution. Frailty was assessed using the MSK-FI, which consists of 1 component related to functional status and 10 medical comorbidities. We used a multivariable logistic regression model to test for the associations between frailty and short-term outcomes, with continuous frailty score as the predictor and additionally adjusted for age and Eastern Cooperative Oncology Group performance status. Results: In total, 447 patients were included in the analysis (median age of 71 years [interquartile range, 68-75]). Most of the patients underwent neoadjuvant treatment (81%), an Ivor Lewis esophagectomy (86%), and minimally invasive surgery (55%). A total of 22 patients (4.9%) died within 90 days of surgery, 144 (32%) had a major complication, 81 (19%) were readmitted, and 31 (7.2%) were discharged to a facility. Of the patients who died within 90 days, 19 had a major complication, yielding a failure-to-rescue rate of 13%. The risk of 30-day major complications (OR, 1.24 [95% CI, 1.09-1.41]; p = 0.001), readmissions (OR, 1.31 [95% CI, 1.13-1.52]; p < 0.001), and discharge to a facility (OR, 1.86 [95% CI, 1.49-2.37]; p < 0.001) increased with increasing frailty. Frailty and 90-day mortality were not associated. Conclusions: Frailty assessment during surgery decision-making can identify patients with a high risk of morbidity.
- Published
- 2024
- Full Text
- View/download PDF
33. Gastric preconditioning via percutaneous angioembolization before esophagectomy in patients at high risk for esophageal leak.
- Author
-
Bevers KC, Sewell M, Bott MJ, Sihag S, Park BJ, Ridouani F, Muñoz FG, Santos E, and Molena D
- Abstract
Anastomotic leaks and stenoses remain critical complications in esophagectomy and are related to conduit perfusion. Surgical gastric preconditioning has been described but requires additional surgery and creates scar tissue, potentially hindering future operation. We sought to evaluate the feasibility and safety of percutaneous gastric preconditioning by angioembolization to improve perfusion of gastric conduits before esophagectomy in a high-risk patient cohort. Patients pending an esophagectomy for cancer and deemed to be high risk for anastomotic complications underwent preconditioning by image-guided angioembolization. Preconditioning was performed on an outpatient basis by means of superselective embolization of the left gastric and short gastric arteries. Intraoperative conduit perfusion evaluation with indocyanine green and postoperative surgical outcomes was reviewed. Seventeen patients underwent gastric preconditioning, with no complications observed. Thirteen of the 17 patients ultimately underwent esophagectomy; the remaining four patients were not candidates for an operation. Patients proceeded to surgery a median of 23 days (interquartile range, 21-27 days) after preconditioning. The intraoperative indocyanine green perfusion of all conduits was appropriate, with no tip demarcation and with a median time to dye uptake of 20s (interquartile range, 15-20s). There were no anastomotic stenoses or leaks noted within the series. Gastric conduit preconditioning by percutaneous angioembolization of the left gastric and short gastric arteries can be performed safely and without operative delay in high-risk patients. Further evaluation of preconditioning for conduit optimization is warranted to limit the critical complications of anastomotic leak and stenosis in esophagectomy., (© The Author(s) 2024. Published by Oxford University Press on behalf of International Society for Diseases of the Esophagus. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
34. Lung resection after initial nonoperative treatment for non-small cell lung cancer.
- Author
-
Dunne EG, Fick CN, Tan KS, Toumbacaris N, Mastrogiacomo B, Adusumilli PS, Rocco G, Molena D, Huang J, Park BJ, Bott MJ, Rusch VR, Sihag S, Isbell JM, Chaft JE, Li BT, Gomez D, Rimner A, Bains MS, and Jones DR
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Neoplasm Staging, Retrospective Studies, Progression-Free Survival, Time Factors, Risk Factors, Treatment Outcome, Databases, Factual, Carcinoma, Non-Small-Cell Lung mortality, Carcinoma, Non-Small-Cell Lung therapy, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Non-Small-Cell Lung surgery, Carcinoma, Non-Small-Cell Lung secondary, Lung Neoplasms mortality, Lung Neoplasms pathology, Lung Neoplasms therapy, Lung Neoplasms surgery, Pneumonectomy adverse effects, Pneumonectomy mortality
- Abstract
Objectives: The study objectives were to assess the outcomes of lung resection in patients with non-small cell lung cancer previously treated with nonoperative treatment and to identify prognostic factors associated with survival., Methods: Patients who underwent surgery (2010-2022) after initial nonoperative treatment at a single institution were identified from a prospectively maintained database. Exclusion criteria included metachronous cancer, planned neoadjuvant therapy, and surgery for diagnostic or palliative indications. Cox models were constructed for overall survival and event-free survival. Survival of patients with stage IV disease was compared with survival of a nonstudy cohort who did not undergo surgery., Results: In total, 120 patients met the inclusion criteria. Initial clinical stage was early stage in 16%, locoregionally advanced in 25%, and metastatic in 59% of patients. The indication for surgery was recurrence in 18%, local persistent disease in 23%, oligoprogression in 22%, and local control of oligometastatic disease in 38% of patients. Grade 3 or greater complications occurred in 5% of patients; 90-day mortality was 3%. Three-year event-free survival and overall survival were 39% and 73%, respectively. Male sex and lymphovascular invasion were associated with shorter event-free survival and overall survival; younger age and prior radiation therapy were associated with shorter overall survival. Patients with stage IV disease who received salvage lung resection had better overall survival than similar patients who received subsequent systemic therapy and no surgery., Conclusions: In this selected, heterogeneous population, lung resection after initial nonoperative treatment for non-small cell lung cancer was safe. Surgery as local consolidative therapy was associated with encouraging outcomes and should be considered for these patients., Competing Interests: Conflict of Interest Statement Dr Adusumilli declares research funding from ATARA Biotherapeutics; is a scientific advisory board member and consultant for ATARA Biotherapeutics, Bayer, Bio4T2, Carisma Therapeutics, Imugene, ImmPactBio, Johnson & Johnson, Orion, and Outpace Bio; has patents, royalties, and intellectual property on mesothelin-targeted chimeric antigen receptor and other T-cell therapies, which have been licensed to ATARA Biotherapeutics; and has an issued patent method for detection of cancer cells using virus and pending patent applications on PD-1 dominant negative receptor, a wireless pulse-oximetry device, and an ex vivo malignant pleural effusion culture system. MSK Cancer Center has licensed intellectual property related to mesothelin-targeted chimeric antigen receptors and T-cell therapies to ATARA Biotherapeutics and has associated financial interests. Dr Rocco has financial relationships with Scanlan International, Medtronic, and Merck. Dr Molena serves on a steering committee for AstraZeneca and as a consultant for Johnson & Johnson, Bristol Myers Squibb, Merck, and Genentech. Dr Park is a consultant for Intuitive Surgical, Medtronic, AstraZeneca, and CEEVRA. Dr Bott is a consultant for AstraZeneca. Dr Rusch reports grant support (institutional) from Genelux and Genentech, travel support from Intuitive Surgical, and travel support and payments from National Institutes of Health/Coordinating Center for Clinical Trials. Dr Sihag is a member of the AstraZeneca Advisory Board. Dr Isbell has stock ownership in LumaCyte and is a consultant/advisory board member for Roche Genentech. Dr Chaft serves as a consultant for AstraZeneca, Bristol Myers Squibb, Flame Biosciences, Regeneron-Sanofi, Guardant Health, and Arcus Biosciences and receives institutional research funding from AztraZeneca, Bristol Myers Squibb, Merck, and Novartis. Dr Li has served as an uncompensated advisor and consultant to Amgen, AstraZeneca, Boehringer Ingelheim, Bolt Biotherapeutics, Daiichi Sankyo, Genentech, and Lilly; has received research grants to his institution from Amgen, AstraZeneca, Bolt Biotherapeutics, Daiichi Sankyo, Genentech, Hengrui USA, and Lilly; has received academic travel support from Amgen, Jiangsu Hengrui Medicine, and MORE Health; and has intellectual property rights as a book author at Karger Publishers and Shanghai Jiao Tong University Press. Dr Gomez reports research funding from Merck, AstraZeneca, Varian, and Bristol Myers Squibb and serves on the advisory boards of MedLearning Group, Medtronic, GRAIL, Johnson & Johnson, AstraZeneca, and Varian. Dr Rimner is a consultant for AstraZeneca, Merck, and MoreHealth, serves as an advisory board member for Merck, and reports institutional grant support from Varian Medical Systems, AstraZeneca, Merck, Pfizer, and Boehringer Ingelheim. Dr Jones serves as a consultant for Merck, AstraZeneca, Genentech, and DAVA Oncology. All other authors reported no conflicts of interest. The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest., (Copyright © 2023 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
35. The Contemporary Management of Esophageal and Gastric Cancer.
- Author
-
Sihag S and Merritt RE
- Subjects
- Humans, Disease Management, Esophageal Neoplasms therapy, Stomach Neoplasms therapy
- Abstract
Competing Interests: Disclosure R.E. Merritt currently serves as a consultant for Astra Zeneca, and a speaker for Astra Zeneca. He does not have any conflicts of interest relevant to this publication.
- Published
- 2024
- Full Text
- View/download PDF
36. Advances in Diagnostic, Staging, and Restaging Evaluation of Esophageal and Gastric Cancer.
- Author
-
Nobel T and Sihag S
- Subjects
- Humans, Endosonography methods, Esophageal Neoplasms pathology, Esophageal Neoplasms diagnosis, Stomach Neoplasms pathology, Stomach Neoplasms diagnosis, Neoplasm Staging methods
- Abstract
The initial endoscopic and staging evaluation of esophagogastric cancers must be accurate and comprehensive in order to select the optimal therapeutic plan for the patient. Esophageal and gastric cancers (and treatment paradigms) are delineated by their proximity to the cardia (within 2 cm). The most frequent and important symptom that informs the initial staging evaluation is dysphagia, which is associated with at least cT3 or locally advanced disease. Endoscopic ultrasound is often needed if earlier stage disease is suspected, preferably in combination with endoscopic mucosal or submucosal resection or fine-needle aspiration of suspicious lymph nodes to enhance staging accuracy., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
37. Immunotherapy for Resectable Locally Advanced Esophageal Carcinoma.
- Author
-
Fick CN, Dunne EG, Sihag S, Molena D, Cytryn SL, Janjigian YY, Wu AJ, Worrell SG, Hofstetter WL, Jones DR, and Gray KD
- Subjects
- Humans, Neoadjuvant Therapy methods, Neoplasm Staging, Esophagectomy methods, Immune Checkpoint Inhibitors therapeutic use, Esophageal Neoplasms therapy, Esophageal Neoplasms pathology, Immunotherapy methods
- Abstract
Background: The current standard of care for locally advanced esophageal and gastroesophageal junction (GEJ) cancers includes neoadjuvant chemoradiotherapy or perioperative chemotherapy with surgical resection; however, disease-free survival in these patients remains poor. Immune checkpoint inhibitors (ICIs) are approved for adjuvant treatment of locally advanced esophageal and GEJ cancers, but their benefit in the perioperative and neoadjuvant settings remains under investigation., Methods: We used the PubMed online database to conduct a literature search to identify studies that investigated immunotherapy for locally advanced esophageal and GEJ carcinoma. A review of ClinicalTrials.gov yielded a list of ongoing trials., Results: Adjuvant nivolumab for residual disease after neoadjuvant chemoradiotherapy and surgery is the only approved immunotherapy regimen for locally advanced esophageal cancer. Early-phase trials investigating the addition of neoadjuvant or perioperative ICIs to standard-of-care multimodality approaches have observed pathologic complete response rates as high as 60%. Response rates are highest for ICIs plus chemoradiotherapy for esophageal squamous cell carcinoma and dual checkpoint inhibition in mismatch repair-deficient adenocarcinomas. Safety profiles are acceptable, with a pooled adverse event rate of 27%. Surgical morbidity and mortality with immunotherapy are similar to historical controls with no immunotherapy, and R0 resection rates are high. When reported, disease-free survival among patients treated with perioperative immunotherapy is promising., Conclusions: Outside of clinical trials, immunotherapy for resectable esophageal carcinoma is limited to the adjuvant setting. Phase III trials investigating neoadjuvant and perioperative immunotherapy are now underway and will provide much-needed data on survival that may ultimately lead to practice-changing recommendations., (Copyright © 2024 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
38. Late recurrence of completely resected stage I to IIIA lung adenocarcinoma.
- Author
-
Fick CN, Dunne EG, Toumbacaris N, Tan KS, Mastrogiacomo B, Park BJ, Adusumilli PS, Molena D, Gray KD, Sihag S, Huang J, Bott MJ, Rocco G, Isbell JM, and Jones DR
- Abstract
Objective: Research into the risk factors associated with late recurrence (>2 years after surgery) of lung adenocarcinoma is limited. We investigated the incidence of and clinicopathologic and genomic features associated with late recurrence of resected stage I-IIIA lung adenocarcinoma., Methods: We performed a retrospective analysis of patients with completely resected pathologic stage I-IIIA lung adenocarcinoma (2010-2019). Patients with a history of lung cancer, neoadjuvant therapy, or mucinous or noninvasive lung adenocarcinoma, or with follow-up of less than 2 years were excluded. Cox and logistic regression modeling were used to compare clinicopathologic variables among patients with no, early (≤2 years), and late recurrence. Comparisons of genomic mutations were corrected for multiple testing., Results: Of the 2349 patients included, 537 developed a recurrence during follow-up. Most recurrences (55% [297/537]) occurred early; 45% (240/537) occurred late. A larger proportion of late recurrences than early recurrences were locoregional (37% vs 29%; P = .047). Patients with late recurrence had more aggressive pathologic features (International Association for the Study of Lung Cancer grade 2 and 3, lymphovascular invasion, visceral pleural invasion) and higher stage than patients without recurrence. Pathologic features were similar between patients with early and late recurrence, except stage IIIA disease was more common in the early cohort. No genomic mutations were associated with late recurrence., Conclusions: Late recurrence of lung adenocarcinoma after resection is more common than previously reported. Patients without disease more than 2 years after surgery who had aggressive pathologic features at the time of resection have an elevated risk of recurrence and may benefit from more aggressive follow-up., Competing Interests: Conflict of Interest Statement B.J.P. has received honoraria from Intuitive Surgical, AstraZeneca, Medtronic, consultants for CEEVRA, and has received research support from Intuitive Surgical. P.S.A. declares research funding from ATARA Biotherapeutics, is a scientific advisory board member/consultant for ATARA Biotherapeutics, Bayer, Bio4T2, Carisma Therapeutics, Imugene, ImmPactBio, Johnson & Johnson, Orion, and Outpace Bio, has patents, royalties, and intellectual property on T-cell therapies, licensed to ATARA Biotherapeutics, and has an issued patent method for detection of cancer cells using virus and pending patent applications on PD-1 dominant negative receptor, a wireless pulse-oximetry device, and an ex vivo malignant pleural effusion culture system. M.S.K. has licensed intellectual property related to mesothelin-targeted chimeric antigen receptors and T-cell therapies to ATARA Biotherapeutics. D.M. serves on a steering committee for AstraZeneca, consults for Johnson & Johnson, Bristol-Myers Squibb, AstraZeneca, and Boston Scientific, and has been an invited speaker for Merck and Genentech. S.S. serves on the AstraZeneca Advisory Board. M.J.B. consults for AstraZeneca Pharmaceuticals, Iovance Biotherapeutics, and Intuitive Surgical and receives research support from Obsidian Therapeutics. G.R. has financial relationships with Scanlan International, AstraZeneca, and Medtronic. J.M.I. has served on advisory boards for AstraZeneca and Merck, as an uncompensated steering board member for Genentech, has received research support from ArcherDx/Invitae, Guardant Health, GRAIL, and Intuitive Surgical and travel support from Intuitive Surgical, and has equity/ownership interest in LumaCyte. D.R.J. serves on the Advisory Council for AstraZeneca and receives research grant support from Merck. All other authors reported no conflicts of interest. The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest., (Copyright © 2024 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
39. Low ppm NO 2 detection through advanced ultrasensitive copper oxide gas sensor.
- Author
-
Sihag S, Dahiya R, Rani S, Berwal P, Jatrana A, Sisodiya AK, Sharma A, and Kumar V
- Abstract
The imperative development of a cutting-edge environmental gas sensor is essential to proficiently monitor and detect hazardous gases, ensuring comprehensive safety and awareness. Nanostructures developed from metal oxides are emerging as promising candidates for achieving superior performance in gas sensors. NO
2 is one of the toxic gases that affects people as well as the environment so its detection is crucial. The present study investigates the gas sensing capability of copper oxide-based sensor for 5 ppm of NO2 gas at 100 °C. The sensing material was synthesized using a facile precipitation method and characterized by XRD, FE-SEM, UV-visible spectroscopy, photoluminescence spectroscopy, XPS and BET techniques. The developed material shows a response equal to 67.1% at optimal temperature towards 5 ppm NO2 gas. The sensor demonstrated an impressive detection limit of 300 ppb, along with a commendable percentage response of 5.2%. Under optimized conditions, the synthesized material demonstrated its high selectivity, as evidenced by the highest percentage response recorded for NO2 gas among NO2 , NH3 , CO, CO2 and H2 S., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
40. Genomic Landscape of Adenocarcinomas Across the Gastroesophageal Junction: Moving on from the Siewert Classification.
- Author
-
Nakauchi M, Walch HS, Nussenzweig S, Carr R, Vos E, Berger MF, Schultz N, Janjigian Y, Wu A, Tang L, Shah P, Jones DR, Coit D, Strong VE, Molena D, and Sihag S
- Abstract
Objective: To investigate how the Siewert classification of gastroesophageal junction adenocarcinomas correlates with genomic profiles., Summary/background Data: Current staging and treatment guidelines recommend that tumors with an epicenter less than 2 cm into the gastric cardia be treated as esophageal cancers, while tumors with epicenter greater than 2 cm into the cardia be staged and treated as gastric cancers. To date, however, few studies have compared the genomic profiles of the 3 Siewert classification groups to validate this distinction., Methods: Using targeted tumor sequencing data on patients with adenocarcinoma of the gastroesophageal junction previously treated with surgery at our institution, we compared genomic features across Siewert classification groups., Results: A total of 350 patients were included: 121 had Siewert type I, 170 type II, and 59 type III. Comparisons by Siewert location revealed that Siewert type I and II were primarily characterized as the chromosomal instability (CIN) molecular subtype and displayed Barrett's metaplasia and p53 and cell cycle pathway dysregulation. Siewert type III tumors, by contrast, were more heterogeneous, including higher proportions of microsatellite instability (MSI) and genomically stable (GS) tumors and more frequently displayed ARID1A and somatic CDH1 alterations, signet ring cell features, and poor differentiation. Overall, Siewert type I and II tumors demonstrated greater genomic overlap with lower esophageal tumors, while Siewert type III tumors shared genomic features with gastric tumors., Conclusions: Overall, our results support recent updates in treatment and staging guidelines. Ultimately, however, molecular rather than anatomic classification may prove more valuable in determining staging, treatment, and prognosis., Competing Interests: The authors report no conflicts of interest., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
41. Advances in the Surgical Management of Esophageal Cancer.
- Author
-
Sihag S
- Subjects
- Humans, Combined Modality Therapy, Disease Management, Esophagectomy, Lymph Node Excision, Esophageal Neoplasms surgery, Esophageal Neoplasms pathology, Esophageal Neoplasms therapy
- Abstract
Radical esophagectomy with two or three-field lymphadenectomy remains the mainstay of curative treatment for localized esophageal cancer, often in combination with systemic chemotherapy and/or radiotherapy. In this article, we describe notable advances in the surgical management of esophageal cancer over the past decade that have led to an improvement in both surgical and oncologic outcomes. In addition, we discuss new approaches to surgical management currently under investigation that have the potential to offer further benefits to appropriately selected patients. These incremental breakthroughs primarily include advances in endoscopic and minimally invasive techniques, perioperative management protocols, as well as the application of local therapies, including surgery, to oligometastatic disease., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
42. High-risk features associated with recurrence in stage I lung adenocarcinoma.
- Author
-
Fick CN, Dunne EG, Vanstraelen S, Toumbacaris N, Tan KS, Rocco G, Molena D, Huang J, Park BJ, Rekhtman N, Travis WD, Chaft JE, Bott MJ, Rusch VW, Adusumilli PS, Sihag S, Isbell JM, and Jones DR
- Abstract
Objective: There is a lack of knowledge regarding the use of prognostic features in stage I lung adenocarcinoma (LUAD). Thus, we investigated clinicopathologic features associated with recurrence after complete resection for stage I LUAD., Methods: We performed a retrospective analysis of patients with pathologic stage I LUAD who underwent R0 resection from 2010 to 2020. Exclusion criteria included history of lung cancer, induction or adjuvant therapy, noninvasive or mucinous LUAD, and death within 90 days of surgery. Fine and Gray competing-risk regression assessed associations between clinicopathologic features and disease recurrence., Results: In total, 1912 patients met inclusion criteria. Most patients (1565 [82%]) had stage IA LUAD, and 250 developed recurrence: 141 (56%) distant and 109 (44%) locoregional only. The 5-year cumulative incidence of recurrence was 12% (95% CI, 11%-14%). Higher maximum standardized uptake value of the primary tumor (hazard ratio [HR], 1.04), sublobar resection (HR, 2.04), higher International Association for the Study of Lung Cancer grade (HR, 5.32 [grade 2]; HR, 7.93 [grade 3]), lymphovascular invasion (HR, 1.70), visceral pleural invasion (HR, 1.54), and tumor size (HR, 1.30) were independently associated with a hazard of recurrence. Tumors with 3 to 4 high-risk features had a higher cumulative incidence of recurrence at 5 years than tumors without these features (30% vs 4%; P < .001)., Conclusions: Recurrence after resection for stage I LUAD remains an issue for select patients. Commonly reported clinicopathologic features can be used to define patients at high risk of recurrence and should be considered when assessing the prognosis of patients with stage I disease., Competing Interests: Conflict of Interest Statement Dr Rocco has financial relationships with Scanlan International, AstraZeneca, and Medtronic. Dr Molena serves on a steering committee for AstraZeneca, consults for Johnson & Johnson, Bristol-Myers Squibb, AstraZeneca, Boston Scientific, and has been an invited speaker for Merck and Genentech. Dr Park has received honoraria from Intuitive Surgical, AstraZeneca, Medtronic, consults for CEEVRA, and has received research support from Intuitive Surgical. Dr Chaft consults for AstraZeneca, Bristol-Myers Squibb, Merck, Regeneron-Sanofi, Guardant Health, and Lily and receives research funding from AztraZeneca, Bristol-Myers Squibb, Merck, and Beigene. Dr Bott consults for AstraZeneca, Iovance Biotherapeutics, Intuitive Surgical, and receives research support from Obsidian Therapeutics. Dr Rusch reports grant support from Genelux and Genentech, and travel support from Intuitive Surgical and National Institutes of Health/Coordinating Center for Clinical Trials. Dr Adusumilli declares research funding from ATARA Biotherapeutics; is a scientific advisory board member and consultant for ATARA Biotherapeutics, Bayer, Bio4T2, Carisma Therapeutics, Imugene, ImmPactBio, Johnson & Johnson, Orion, and Outpace Bio; has patents, royalties, and intellectual property on T-cell therapies licensed to ATARA Biotherapeutics; and has an issued patent method for detection of cancer cells using virus and pending patent applications on PD-1 dominant negative receptor, a wireless pulse-oximetry device, and an ex vivo malignant pleural effusion culture system. Dr Sihag serves on the AstraZeneca advisory board. Dr Isbell has served on advisory boards for AstraZeneca and Merck; as an uncompensated steering board member for Genentech; has received research support from ArcherDx/Invitae, Guardant Health, GRAIL, Intuitive Surgical; has received travel support from Intuitive Surgical; and has equity/ownership interest in LumaCyte. Dr Jones serves on the advisory council for AstraZeneca and receives research grant support from Merck. All other authors reported no conflicts of interest. The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest., (Copyright © 2024 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
43. A New Functional Threshold for Minimally Invasive Lobectomy.
- Author
-
Vanstraelen S, Tan KS, Dycoco J, Adusumilli PS, Bains MS, Bott MJ, Downey RJ, Gray KD, Huang J, Isbell JM, Molena D, Park BJ, Rusch VW, Sihag S, Jones DR, and Rocco G
- Abstract
Objective: To assess the performance of a lower predicted postoperative (ppo) forced expiratory volume in 1 second (FEV1) or diffusion capacity of the lung for carbon monoxide (DLCO) (ppoFEV1/ppoDLCO) threshold to predict cardiopulmonary complications after minimally invasive surgery (MIS) lobectomy., Summary Background Data: Although MIS is associated with better postoperative outcomes than open surgery, MIS uses risk-assessment algorithms developed for open surgery. Moreover, several different definitions of cardiopulmonary complications are used for assessment., Methods: All patients who underwent MIS lobectomy for clinical stage I-II lung cancer from 2018 to 2022 at our institution were considered. The performance of a ppoFEV1/ppoDLCO threshold of <45% was compared against that of the current guideline threshold of <60%. Three different definitions of cardiopulmonary complications were compared: Society of Thoracic Surgeons (STS), European Society of Thoracic Surgeons (ESTS), and Berry et al., Results: In 946 patients, the ppoFEV1/ppoDLCO threshold of <45% was associated with a higher proportion correctly classified (79% [95% CI, 76%-81%] vs. 65% [95% CI, 62%-68%]; P<0.001). The complication with the biggest difference in incidence between ppoFEV1/ppoDLCO of 45%-60% and >60% was prolonged air leak (33 [13%] vs. 34 [6%]; P<0.001). The predicted probability curves for cardiopulmonary complications were higher for the STS definition than for the ESTS or Berry definitions across ppoFEV1 and ppoDLCO values., Conclusions: The ppoFEV1/ppoDLCO threshold of <45% more accurately classified patients for cardiopulmonary complications after MIS lobectomy, emphasizing the need for updated risk-assessment guidelines for MIS lobectomy to optimize additional cardiopulmonary function evaluation., Competing Interests: The authors have no conflicts of interest., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
44. Comparison of Hemopoietic Biochemical Parameters in the First, Second, and Third Trimester of Pregnant Females Attending a Tertiary Care Hospital of Western Rajasthan.
- Author
-
Bissa MS, Rawtani J, Sihag S, and Bissa R
- Abstract
Background: Pregnant women constitute a high-risk group for nutrient deficiency anemia which may be associated with detrimental effects on maternal and infant health., Objectives: This study aimed to assess and compare hematological and biochemical changes across trimesters in pregnant women, considering parameters such as hemoglobin, serum iron, unsaturated iron-binding capacity (UIBC), total iron-binding capacity (TIBC), ferritin, vitamin B12, and folic acid. The research sought to identify mean value differences, correlations, and potential implications for maternal healthcare practices., Methods: A hospital-based prospective observational study was conducted, involving 60 primigravida women with singleton pregnancies. The subjects were assessed during the first, second, and third trimesters. Biochemical parameters were assessed using standard methods, and statistical analysis was performed to identify significance and correlations., Results: The study revealed a significant decline in hemoglobin, serum iron, ferritin, vitamin B12, and folic acid as pregnancy advanced. Hemoglobin levels decreased from 11.40 g/dl (first trimester) to 10.43 g/dl (third trimester). Serum iron exhibited a decline from 109.73 µg/dl (first trimester) to 94.03 µg/dl (third trimester). Serum ferritin decreased from 24.93 ng/ml (first trimester) to 18.21 ng/ml (third trimester). Vitamin B12 levels dropped from 255.92 pg/ml (first trimester) to 92.13 pg/ml (third trimester). Folic acid levels decreased from 13.82 ng/ml (first trimester) to 11.77 ng/ml (third trimester). UIBC and TIBC concentrations increased progressively across trimesters. Statistical evaluations confirmed the significance of these trends. The coefficient of correlation indicated positive relationships between hemoglobin and serum iron, ferritin, folic acid, and vitamin B12. Positive correlation between serum iron and ferritin, vitamin B12, and negative with folic acid. Serum ferritin negatively correlated with vitamin B12 and folic acid. Serum folic acid and vitamin B12 are positively correlated., Conclusion: The findings emphasize the dynamic nature of hematological and biochemical changes during pregnancy. The observed trends have profound implications for maternal healthcare practices, urging targeted interventions, early monitoring, and supportive supplementation. Recognizing these variations contributes to the optimization of health outcomes for both mother and child., Competing Interests: The authors have declared that no competing interests exist., (Copyright © 2024, Bissa et al.)
- Published
- 2024
- Full Text
- View/download PDF
45. Treatment of esophageal adenocarcinoma in patients with a history of bariatric surgery.
- Author
-
Nobel T, Sewell M, Boerner T, Bains MS, Bott MJ, Gerdes H, Gray K, Nishimura M, Park BJ, Shah P, Sihag S, Jones DR, and Molena D
- Subjects
- Humans, Middle Aged, Obesity complications, Obesity surgery, Gastrectomy adverse effects, Retrospective Studies, Barrett Esophagus etiology, Barrett Esophagus surgery, Barrett Esophagus diagnosis, Esophageal Neoplasms etiology, Esophageal Neoplasms surgery, Esophageal Neoplasms diagnosis, Adenocarcinoma etiology, Adenocarcinoma surgery, Adenocarcinoma diagnosis, Bariatric Surgery adverse effects, Gastroesophageal Reflux surgery, Gastroesophageal Reflux complications, Obesity, Morbid surgery
- Abstract
Background: The relationship among obesity, bariatric surgery, and esophageal adenocarcinoma (EAC) is complex, given that some bariatric procedures are thought to be associated with increased incidence of reflux and Barrett's esophagus. Previous bariatric surgery may complicate the use of the stomach as a conduit for esophagectomy. In this study, we presented our experience with patients who developed EAC after bariatric surgery and described the challenges encountered and the techniques used., Methods: We conducted a retrospective review of our institutional database to identify all patients at our institution who were treated for EAC after previously undergoing bariatric surgery., Results: In total, 19 patients underwent resection with curative intent for EAC after bariatric surgery, including 10 patients who underwent sleeve gastrectomy. The median age at diagnosis of EAC was 63 years; patients who underwent sleeve gastrectomy were younger (median age, 56 years). The median time from bariatric surgery to EAC was 7 years. Most patients had a body mass index (BMI) score of >30 kg/m
2 at the time of diagnosis of EAC; approximately 40% had class III obesity (BMI score > 40 kg/m2 ). Six patients (32%) had known Barrett's esophagus before undergoing a reflux-increasing bariatric procedure. Sleeve gastrectomy patients underwent esophagectomy with gastric conduit, colonic interposition, or esophagojejunostomy. Only 1 patient had an anastomotic leak (after esophagojejunostomy)., Conclusion: Endoscopy should be required both before (for treatment selection) and after all bariatric surgical procedures. Resection of EAC after bariatric surgery requires a highly individualized approach but is safe and feasible., (Copyright © 2024 Society for Surgery of the Alimentary Tract. Published by Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
46. Mucinous Carcinoma of the Breast: A Case Report.
- Author
-
Rey J, Shukla S, Acharya S, Gadkari P, and Sihag S
- Abstract
This case report presents the diagnostic journey of a 65-year-old female presenting with symptoms suggestive of breast pathology, ultimately diagnosed with mucinous carcinoma, following comprehensive clinical evaluation and histopathological confirmation. Initial assessments indicated a fibroadenoma; however, subsequent histopathological examination revealed mucinous carcinoma, highlighting the importance of histopathological confirmation in establishing definitive diagnoses. The case underscores the challenges in distinguishing between benign and malignant breast lesions based on clinical presentation and imaging findings alone. The multidisciplinary approach facilitated discussions regarding treatment options tailored to the patient's clinical and pathological characteristics. This case emphasizes the significance of a comprehensive diagnostic approach, integrating clinical evaluation, imaging studies, and histopathological analysis, in ensuring accurate diagnosis and guiding optimal management strategies for patients with breast cancer., Competing Interests: The authors have declared that no competing interests exist., (Copyright © 2024, Rey et al.)
- Published
- 2024
- Full Text
- View/download PDF
47. A Case Report of Malignant Mesenchymal Tumor Presenting As Anterior Thigh Swelling: A Diagnostic Challenge.
- Author
-
Rey J, Shukla S, Acharya S, Gadkari P, and Sihag S
- Abstract
This case report describes the presentation, diagnostic challenges, and management of a 64-year-old male with a malignant mesenchymal tumor presenting as a swelling in the anterior thigh. Despite initial misdiagnosis and treatment at a local hospital, the swelling worsened, leading to referral to a specialized hospital. Further investigations, including blood tests, ultrasonography (USG), and MRI, revealed a large solid cystic lesion compressing adjacent muscles, indicative of soft tissue sarcoma (STS). A skin biopsy confirmed the diagnosis of a malignant mesenchymal tumor. The patient, also suffering from hypertension and diabetes mellitus, was subsequently referred to the oncology department for further management. This case underscores the importance of thorough evaluation and histopathological confirmation for accurate diagnosis and management of STS, particularly in the context of atypical presentations and comorbidities., Competing Interests: The authors have declared that no competing interests exist., (Copyright © 2024, Rey et al.)
- Published
- 2024
- Full Text
- View/download PDF
48. Clinical and molecular characteristics of early-onset vs average-onset esophagogastric cancer.
- Author
-
Lumish MA, Walch H, Maron SB, Chatila W, Kemel Y, Maio A, Ku GY, Ilson DH, Won E, Li J, Joshi SS, Gu P, Schattner MA, Laszkowska M, Gerdes H, Jones DR, Sihag S, Coit DG, Tang LH, Strong VE, Molena D, Stadler ZK, Schultz N, Janjigian YY, and Cercek A
- Subjects
- Humans, Female, Adolescent, Young Adult, Adult, Middle Aged, Aged, Aged, 80 and over, Cardia metabolism, Esophagogastric Junction metabolism, Esophagogastric Junction pathology, Retrospective Studies, Esophageal Neoplasms epidemiology, Esophageal Neoplasms genetics, Stomach Neoplasms diagnosis, Stomach Neoplasms epidemiology, Stomach Neoplasms genetics, Adenocarcinoma epidemiology, Adenocarcinoma genetics, Carcinoma, Signet Ring Cell metabolism, Carcinoma, Signet Ring Cell pathology
- Abstract
Background: The rate of esophagogastric cancer is rising among individuals under 50 years of age. It remains unknown whether early-onset esophagogastric cancer represents a unique entity. This study investigated the clinical and molecular characteristics of early-onset and average-onset esophagogastric cancer ., Methods: We reviewed the Memorial Sloan Kettering Cancer Center gastric, esophageal, and gastroesophageal junction cancer database. Associations between baseline characteristics and tumor and germline molecular alterations were compared between those with early-onset and average-onset esophagogastric cancer using Fisher exact tests and the Benjamini-Hochberg method for multiple-hypothesis correction., Results: We included 1123 patients with early-onset esophagogastric cancer (n = 219; median age = 43 years [range = 18-49 years]) and average-onset esophagogastric cancer (n = 904; median age = 67 years [range = 50-94 years]) treated between 2005 and 2018. The early-onset group had more women (39% vs 28%, P = .002). Patients with early-onset esophagogastric cancer were more likely to have a gastric primary site (64% vs 44%, P < .0001). The signet ring cell and/or diffuse type was 3 times more common in the early-onset esophagogastric cancer group (31% vs 9%, P < .0001). Early-onsite tumors were more frequently genomically stable (31% vs 18%, P = .0002) and unlikely to be microsatellite instability high (2% vs 7%, P = .003). After restricting to adenocarcinoma and signet ring cell and/or diffuse type carcinomas, we observed no difference in stage (P = .40) or overall survival from stage IV diagnosis (median = 22.7 vs 22.1 months, P = .78)., Conclusions: Our study supported a preponderance of gastric primary disease sites, signet ring histology, and genomically stable molecular subtypes in early-onset esophagogastric cancer. Our findings highlight the need for further research to define the underlying pathogenesis and strategies for early detection and prevention., (© The Author(s) 2023. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
49. Biologic versus synthetic prosthesis for chest wall reconstruction: a matched analysis.
- Author
-
Vanstraelen S, Bains MS, Dycoco J, Adusumilli PS, Bott MJ, Downey RJ, Huang J, Isbell JM, Molena D, Park BJ, Rusch VW, Sihag S, Allen RJ Jr, Cordeiro PG, Coriddi MR, Dayan JH, Disa JJ, Matros E, McCarthy CM, Nelson JA, Stern C, Shahzad F, Mehrara B, Jones DR, and Rocco G
- Subjects
- Humans, Postoperative Complications epidemiology, Postoperative Complications surgery, Postoperative Complications etiology, Treatment Outcome, Prostheses and Implants adverse effects, Retrospective Studies, Thoracic Wall surgery, Biological Products
- Abstract
Objectives: The aim of this study was to compare postoperative outcomes between biologic and synthetic reconstructions after chest wall resection in a matched cohort., Methods: All patients who underwent reconstruction after full-thickness chest wall resection from 2000 to 2022 were reviewed and stratified by prosthesis type (biologic or synthetic). Biologic prostheses were of biologic origin or were fully absorbable and incorporable. Integer matching was performed to reduce confounding. The study end point was surgical site complications requiring reoperation. Multivariable analysis was performed to identify associated risk factors., Results: In total, 438 patients underwent prosthetic chest wall reconstruction (unmatched: biologic, n = 49; synthetic, n = 389; matched: biologic, n = 46; synthetic, n = 46). After matching, the median (interquartile range) defect size was 83 cm2 (50-142) for the biologic group and 90 cm2 (48-146) for the synthetic group (P = 0.97). Myocutaneous flaps were used in 33% of biologic reconstructions (n = 15) and 33% of synthetic reconstructions (n = 15) in the matched cohort (P = 0.99). The incidence of surgical site complications requiring reoperation was not significantly different between biologic and synthetic reconstructions in the unmatched (3 [6%] vs 29 [7%]; P = 0.99) and matched (2 [4%] vs 4 [9%]; P = 0.68) cohorts. On the multivariable analysis, operative time [adjusted odds ratio (aOR) = 1.01, 95% confidence interval (CI), 1.00-1.01; P = 0.006] and operative blood loss (aOR = 1.00, 95% CI, 1.00-1.00]; P = 0.012) were associated with higher rates of surgical site complications requiring reoperation; microvascular free flaps (aOR = 0.03, 95% CI, 0.00-0.42; P = 0.024) were associated with lower rates., Conclusions: The incidence of surgical site complications requiring reoperation was not significantly different between biologic and synthetic prostheses in chest wall reconstructions., (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
50. Expression profiling of immune genes associated with black pepper ( Piper nigrum ) powder supplementation in the diets of broiler chickens.
- Author
-
Chalana G, Sihag S, Kumar A, and Magotra A
- Subjects
- Animals, Powders, Escherichia coli, Toll-Like Receptor 2, Toll-Like Receptor 4, Diet veterinary, Dietary Supplements, Animal Feed analysis, Chickens genetics, Piper nigrum
- Abstract
The present study was conducted on three hundred commercial broiler chicks with the aim to evaluate the effect of black pepper supplementation on expression of TLR gene where the negative control (T1) group was given basal diet without antibiotic and in the control group (T2) basal diet with antibiotic was fed, third (T3), fourth (T4), fifth (T5) and sixth (T6) groups were supplemented with black pepper powder (BPP) at levels 0.25, 0.5, 0.75 and 1%, respectively in diet. After 42 days, a significant reduction ( p < 0.05) in ileal E. coli count and a higher value of Lactobacilli was recorded in the various black pepper powder supplemented groups, and they differed significantly ( p < 0.05) from negative control. The mRNA expression levels of Toll-like receptors (TLR 2 and TLR 4) had shown significant ( p < 0.05) changes in experimental groups. The TLR 2 and TLR 4 genes revealed differential expression in all black pepper supplemented groups in comparison to negative control and control group, while TLR 7 did not show any significant change. Thus, supplementation of black pepper powder can be exploited as an immunomodulator to enhance adaptive immune response of broiler chicks after validation on large number of samples.
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.